Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.

Serkan OzakbasBilge Piri Cinar Cavid BabaGorkem KosehasanogullariMultiple Sclerosis Research Group

Published in: Acta neurologica Scandinavica (2022)

Our study includes the most comprehensive NEDA-3 data from real world evidence and supports the idea that NEDA-3 can be an effective early predictor of progression-free status at treatment follow-up of up to 10 years.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms
electronic health record
combination therapy
systemic lupus erythematosus
replacement therapy